他汀相关免疫介导坏死性肌病与特发性炎症性肌病全因死亡率比较
这项回顾性队列研究纳入142例成人特发性炎症性肌病(IIM)患者,其中41例为他汀相关免疫介导坏死性肌病(IMNM)。他汀相关IMNM的全因死亡率高于其他IIM(31.7% vs 23.8%),但校正年龄、糖尿病和高脂血症后差异不再显著,提示合并症可识别高危表型。
要点
- 他汀相关IMNM患者全因死亡率高于其他IIM亚型(31.7% vs 23.8%)。
- 死亡主因为心肺事件和感染,而非肌病本身直接致死。
- 年龄≥60岁且anti-HMGCR阳性的他汀相关IMNM患者生存率最低。
核心结论
- 他汀相关IMNM的全因死亡率高于其他特发性炎症性肌病亚型。
- 校正年龄、糖尿病和高脂血症后,死亡率差异不再具有统计学意义。
- 年龄≥60岁的他汀相关IMNM患者在四个分层中生存率最低。
研究设计与样本
- 回顾性队列研究,纳入三级学术医疗中心评估的142例成人特发性炎症性肌病患者。
- 他汀相关IMNM定义为IMNM伴近期他汀暴露,IIM按标准标准定义。
- 主要结局为全因死亡率,主要分析采用年龄校正Cox比例风险模型,另用倾向评分加权Cox模型校正年龄、糖尿病和高脂血症。
主要发现
- 142例IIM中41例为他汀相关IMNM,该组患者年龄更大且病程更短(P<0.05)。
- 他汀相关IMNM全因死亡率为31.7%(13/41),其他IIM为23.8%(24/101)。
- 未校正风险比(HR)为2.55(95%CI 1.24-5.24;P=0.011),死亡主因为心肺事件和感染。
- 年龄校正后HR为1.98(95%CI 0.97-4.03),进一步校正糖尿病和高脂血症后HR为1.70(95%CI 0.71-4.08)。
- 按anti-HMGCR状态和年龄(切点60岁)联合分层,年龄≥60岁的他汀相关IMNM患者生存率在四层中最低(log-rank P=0.036)。
关键数值与推荐
- 他汀相关IMNM定义:IMNM伴近期他汀暴露。
- IIM定义:按标准标准。
- 年龄分层切点:60岁。
临床怎么用
- 对年龄≥60岁且anti-HMGCR阳性的他汀相关IMNM患者应加强监测与综合管理。
- 评估他汀相关IMNM患者时需关注糖尿病、高脂血症等代谢合并症对预后的影响。
- 死亡主因为心肺事件和感染,提示需重视合并症筛查与感染防控。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Statin-associated immune-mediated necrotizing myopathy (IMNM) is a distinct idiopathic inflammatory myopathy (IIM) associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies. The present study determined all-cause mortality among patients with statin-associated IMNM. METHODS: In this retrospective cohort study of 142 adult patients with IIM evaluated at a tertiary academic medical centre, statin-associated IMNM was defined by IMNM with recent statin exposure. IIM was defined by standard criteria. The primary outcome was all-cause mortality. Age-adjusted Cox proportional hazards models were the primary analyses with additional adjustments for age, diabetes mellitus and hyperlipidaemia with propensity score-weighted Cox models. RESULTS: Among 142 patients with IIM, 41 were statin-associated IMNM who were older and had shorter disease duration (P < 0.05). All-cause mortality was higher in statin-associated IMNM (31.7%, 13/41) than in IIM (23.8%, 24/101) (unadjusted hazard ratio [HR] 2.55, 95% CI 1.24-5.24; P = 0.011), with cardiopulmonary events and infections the major causes of death. In unadjusted analysis, statin-associated IMNM was associated with higher mortality (HR 2.55, 95% CI 1.24-5.24) and attenuated after age adjustment (HR 1.98, 95% CI 0.97-4.03) and was no longer statistically significant after adjustment for diabetes and hyperlipidaemia (HR 1.70, 95% CI 0.71-4.08). Joint stratification by anti-HMGCR status and age (cut-off 60 years) demonstrated that older patients with statin-associated IMNM had the lowest survival among the four strata (log-rank P = 0.036). CONCLUSIONS: Statin-associated IMNM is associated with higher mortality than other myositis subtypes; this excess attenuates after adjustment for age and cardiometabolic comorbidity, indicating these pre-existing conditions identify a higher-risk clinical phenotype.
引用
- Edeh OM, Dinh TN, Muruganandam M, et al. All-cause mortality in statin-associated immune-mediated necrotizing myopathy compared with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2026. PMID: 42786572. doi:10.1093/rheumatology/keag536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。